Vertex Pharmaceuticals for rare lung diseases.

• ARIKAYCE: A drug for the treatment of Mycobacterium avium complex lung disease as part of a combination antibacterial drug regimen for adult patients.
• Brensocatib: An oral reversible inhibitor of dipeptidyl peptidase 1 currently in development for the treatment of patients with bronchiectasis and other neutrophil-mediated diseases.
• Treprostinil Palmitil Inhalation Powder: An inhaled formulation of a treprostinil prodrug in development for the treatment of pulmonary arterial hypertension and other rare pulmonary disorders.

Insmed (INSM) is a biopharmaceutical company that develops and commercializes therapies for serious and rare diseases. As such, it sells its prescription drug products primarily to other companies within the healthcare supply chain, rather than directly to individual patients.

The major customers of Insmed typically fall into the following categories:

• Pharmaceutical Wholesale Distributors: These large distributors purchase drugs from manufacturers and then supply them to pharmacies, hospitals, and other healthcare providers. Major public companies in this sector include:
  • McKesson Corporation (MCK)
  • AmerisourceBergen Corporation (ABC)
  • Cardinal Health, Inc. (CAH)
• Specialty Pharmacies: For drugs treating rare and complex diseases, like those offered by Insmed, distribution often involves specialty pharmacies. These pharmacies handle specific storage, handling, and patient support requirements. While many are privately held or divisions of larger companies, they represent a critical customer segment.
• Hospitals and Healthcare Systems: Healthcare institutions purchase drugs for use in inpatient and outpatient settings.

Will Lewis joined Insmed in 2012 as President and Chief Executive Officer and became Chair of the Board of Directors in November 2018. He is the former Co-Founder, President, and Chief Financial Officer of Aegerion Pharmaceuticals, Inc., which was acquired by Amryt in 2019. Prior to Aegerion, Mr. Lewis spent over 10 years working in investment banking in the U.S. and Europe.

Sara Bonstein joined Insmed in January 2020. She brings over two decades of operational and financial leadership experience in the life sciences industry, having raised over $2 billion in the capital marketplace. Before Insmed, Ms. Bonstein served as Chief Financial Officer and Chief Operating Officer at OncoSec Medical and as Chief Financial Officer at Advaxis, Inc. She also held various positions of increasing responsibility at Eli Lilly & Company and Johnson & Johnson.

Michael Smith joined Insmed in 2014 as Corporate Counsel and was promoted to Chief Legal Officer in January 2024. He has more than 20 years of legal expertise. Before joining Insmed, Mr. Smith served as Associate General Counsel at ViroPharma Incorporated from 2008 until its acquisition by Shire plc in 2014. He also previously worked for Bristol-Myers Squibb and the law firm of Reed Smith.

Roger Adsett serves as the Chief Operating Officer for Insmed. He is an experienced and visionary healthcare executive.

Martina Flammer is the Chief Medical Officer at Insmed. Her experience spans clinical development, medicine, and commercial areas.

Key Risks to Insmed (INSM)

1. Dependence on Key Products and Pipeline Success: Insmed's financial performance is heavily reliant on the continued success of its commercial product, ARIKAYCE, and the successful regulatory approval and commercialization of its pipeline assets, particularly Brensocatib and Treprostinil Palmitil Inhalation Powder (TPIP). Unexpected challenges in production, regulatory approval processes, or market acceptance for these limited number of products could significantly impact the company's financial stability and growth prospects.
2. Profitability Challenges and Sustained Losses: Insmed has historically reported significant accumulated deficits and ongoing net losses, reflecting the high costs associated with research and development and commercialization efforts. While the company projects future revenue growth, there is a risk that it may face continued challenges in achieving sustained profitability and positive cash flow, potentially requiring additional capital to fund operations and development programs.
3. Competitive Pressures and Regulatory/Clinical Trial Risks: Operating within the highly competitive biopharmaceutical industry, Insmed faces intense competition for its approved product ARIKAYCE and its pipeline candidates in rare disease markets. Additionally, as a biotechnology company, Insmed is subject to inherent regulatory and clinical trial risks, including the complexities and uncertainties of obtaining and maintaining product approvals across different regions, and the potential for adverse clinical trial outcomes or regulatory decisions.

The launch of Liquidia Corporation's YUTREPIA (treprostinil inhalation powder) poses a clear emerging competitive threat to Insmed's Treprostinil Palmitil Inhalation Powder (TPIP) for the treatment of pulmonary arterial hypertension and other rare pulmonary disorders. Both are inhaled treprostinil-based therapies, with YUTREPIA already approved and launched, creating an established competitor in the market segment that TPIP aims to enter.

Insmed (symbol: INSM) focuses on developing therapies for serious and rare diseases, with key products targeting specific, high-need markets.

ARIKAYCE (amikacin liposome inhalation suspension)

ARIKAYCE is approved for the treatment of refractory Mycobacterium avium complex (MAC) lung disease. The total Nontuberculous Mycobacterial Treatment Market in the U.S. was approximately $360 million in 2023, with ARIKAYCE contributing roughly $223 million in revenue for refractory MAC in the same year. Insmed anticipates full-year 2026 global revenues for ARIKAYCE to be in the range of $450 million to $470 million. Market size analyses for ARIKAYCE are available across the 7MM (United States, Germany, France, Italy, Spain, United Kingdom, and Japan) with projections extending to 2034.

Brensocatib (BRINSUPRI)

Brensocatib is developed for bronchiectasis, particularly non-cystic fibrosis bronchiectasis (NCFB). The total bronchiectasis market size in the 7MM (United States, EU4 - Germany, France, Italy, Spain, United Kingdom, and Japan) was approximately $1,581.2 million in 2023. This market is projected to grow to approximately $7,463.5 million by 2035 for NCFB alone. In 2023, the U.S. bronchiectasis market was approximately $740.9 million, representing about 47% of the total market revenue for the 7MM, while EU4 and the UK accounted for approximately $772.5 million, and Japan for roughly $67.9 million. Insmed expects Brensocatib to achieve over $5 billion in sales in the U.S., Europe, and Japan for its initial indication. The global bronchiectasis market was valued at $597.25 million in 2024 and is projected to reach $959.14 million by 2032.

Treprostinil Palmitil Inhalation Powder (TPIP)

Treprostinil Palmitil Inhalation Powder (TPIP) is being evaluated for the treatment of pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD). The global Treprostinil market, which includes various formulations of treprostinil, was valued at $135 million in 2024 and is projected to reach $172 million by 2034. The broader Pulmonary Arterial Hypertension Treatment Market in the 7MM was valued at approximately $6,971 million in 2025 and is anticipated to increase by 2034. For PH-ILD, the market size in the 7MM was approximately $3 billion in 2024, with projections for growth between 2025 and 2034. Specifically, the U.S. market for PH-ILD was approximately $2 billion in 2024, while EU4 and the UK had a market size of approximately $480 million, and Japan had a market size of approximately $285 million in 2024.

Insmed (INSM) is poised for significant revenue growth over the next two to three years, driven primarily by the successful launch and anticipated global expansion of its new product, the continued performance and potential label expansion of its established therapy, and the advancement of its late-stage pipeline assets.

1. Global Launch and Expansion of BRINSUPRI (brensocatib) for Bronchiectasis: BRINSUPRI, launched in the U.S. in Q3 2025, is a primary driver of Insmed's projected revenue growth. The company reported approximately $172.7 million in full-year 2025 revenue for BRINSUPRI and expects at least $1 billion in revenue for the product in 2026. This strong early performance is anticipated to be further bolstered by planned commercial launches in Europe, the United Kingdom, and Japan throughout 2026, subject to regulatory approvals. Insmed projects over $5 billion in peak sales from the initial bronchiectasis market alone.
2. Continued Growth of ARIKAYCE: ARIKAYCE, Insmed's commercialized therapy for Mycobacterium avium complex (MAC) lung disease, continues to demonstrate robust growth. Global revenue for ARIKAYCE grew 19% in 2025, reaching $433.8 million, surpassing the company's guidance. Insmed forecasts global ARIKAYCE revenues to be between $450 million and $470 million for 2026. This growth is supported by increased adoption in key international markets, with Japan experiencing 40% growth in 2025 and Europe showing even faster growth from a smaller base.
3. Potential Label Expansion for ARIKAYCE: The ongoing Phase 3 ENCORE trial for ARIKAYCE in patients with newly diagnosed or recurrent MAC lung disease who have not yet started antibiotics is expected to report topline data in March or April 2026. Positive results from this trial could lead to a supplementary New Drug Application (sNDA) to the FDA in the second half of 2026, potentially expanding ARIKAYCE's label to include all patients with MAC lung disease and significantly broadening its addressable market.
4. Advancement and Anticipated Launches of Treprostinil Palmitil Inhalation Powder (TPIP): Insmed's pipeline candidate, Treprostinil Palmitil Inhalation Powder (TPIP), is progressing with positive Phase 2b results in pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD). The company plans to initiate Phase 3 trials for TPIP in PH-ILD in late 2025 and in PAH in early 2026. Additionally, Insmed anticipates initiating further Phase 3 studies for TPIP in progressive pulmonary fibrosis (PPF) and idiopathic pulmonary fibrosis (IPF) in the second half of 2026. These indications represent multi-billion dollar market opportunities that could contribute to future revenue growth upon successful development and approval.

Share Repurchases

There is no information available regarding share repurchases made or authorized by Insmed over the last 3-5 years.

Share Issuance

• In May 2024, Insmed completed an underwritten public offering of 12,621,359 shares of its common stock at $51.50 per share, resulting in approximately $650 million in gross proceeds. The net proceeds from this offering and an "at-the-market" (ATM) program totaled $713.2 million.
• The proceeds from the share issuance were intended to fund the continued research and development of brensocatib, commercialization activities for brensocatib and ARIKAYCE, further research and development of treprostinil palmitil inhalation powder (TPIP), and for general corporate purposes, including business expansion activities.
• As of the fourth quarter of 2025, Insmed had 216 million shares outstanding, reflecting a 1.1% increase from the previous quarter.

Inbound Investments

There is no information available regarding large inbound investments made in Insmed by third-parties, such as strategic partners or private equity firms, over the last 3-5 years.

Outbound Investments

• In December 2025, Insmed acquired INS1148, an investigational monoclonal antibody that was Phase 2-ready.
• This acquisition contributed to an increase in research and development expenses for the full year 2025.
• Insmed plans to advance Phase 2 development programs for INS1148, initially focusing on interstitial lung disease and moderate to severe asthma.

Capital Expenditures

• For the fiscal year 2025, Insmed invested $32.6 million in capital expenditures, which were primarily directed towards funding long-term assets and infrastructure.
• In the fourth quarter of 2025, capital expenditures amounted to $16.6 million, marking a substantial increase of 586.1% from the prior quarter.
• The company anticipates that its pre-clinical research programs will constitute less than 20% of its overall expenditures.